Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers

Inclusion Criteria: * Male and female patients * Requiring cisplatin therapy (\>80mg/m2) against advanced head and neck carcinoma, non-small cell lung cancer stage IIIB/IV, bladder transitional cell carcinoma locally advanced or metastatic, which are not amenable to surgical resection or ablation with curative intent * An Eastern Cooperative Oncology Group performance status (ECOG PS) \<2 * Normal renal, hepatic and bone marrow function * Physician's assessment of life expectancy: 4-10 months * Aged \> 18 years * Evidence of acute renal injury as assessed by percent increase of NGAL concentration in spot urine \> 3500% over baseline values at day 2 post-cisplatin infusion * Written informed consent Exclusion Criteria: * Specific contraindication to MSC infusion * Serious concomitant diseases not adequately responding to specific therapy * Symptomatic brain metastases * Pregnancy * Previous cisplatin infusion